Calreticulin and JAK2V617F Mutations in Essential Thrombocythemia and Their Potential Role in Diagnosis and Prognosis
Najmaldin Saki
Abstract
Open-access reader
Najmaldin Saki
Abstract
Open-access reader
Mutation in calreticulin (CALR) has been recently detected in essential thrombocythemia (ET) patients lacking JAK2V617F mutation. The absence of JAK2V617F mutation in 50% of patients with ET has indicated the importance of new markers for disease diagnosis, including CALR. Considering the detection of CALR in these patients, in this paper we study the structure and function of CALR protein and JAK2V617F as well as their diagnostic and prognostic role in ET patients.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Mutation in calreticulin (CALR) has been recently detected in essential thrombocythemia (ET) patients lacking JAK2V617F mutation. The absence of JAK2V617F mutation in 50% of patients with ET has indicated the importance of new markers for disease diagnosis, including CALR. Considering the detection of CALR in these patients, in this paper we study the structure and function of CALR protein and JAK2V617F as well as their diagnostic and prognostic role in ET patients.
Key concepts: Calreticulin, Essential thrombocythemia, Mutation, Medicine, Internal medicine, Cancer research, Genetics, Polycythemia vera